Name, scope, and intended-use boundary
Melatonin test kits are collection and analytical systems for measuring melatonin or a major metabolite in human specimens. They are not one standardized home sleep diagnostic. Common specimens include saliva, plasma or serum, and urinary 6-sulfatoxymelatonin. A product may be intended for research, professional laboratory use, or home collection followed by laboratory analysis. Its analyte, sensitivity, and intended use must be evaluated separately.
Testing melatonin concentration in a person is different from testing the amount contained in a supplement tablet or gummy. The first assesses biological specimens and circadian timing; the second is a product-content and quality analysis. Even an accurate laboratory concentration is not automatically validated to diagnose insomnia, sleep apnea, depression, pineal dysfunction, or a proposed condition called “melatonin deficiency.”
Physiology and specimen differences
Melatonin is strongly influenced by the endogenous circadian clock and environmental light and usually rises during biological night. The timing of its onset, peak, decline, or overnight production is often more relevant than whether one value is high or low. Clock time, time relative to habitual sleep, recent schedule, shift work, time-zone travel, and light reaching the eyes all affect interpretation. The same clock time need not represent the same biological phase in two people.
Plasma concentrations are generally higher than salivary concentrations and support dense sampling, although repeated blood collection is more complex. Saliva is practical for serial home collection, but its range and reference values must be method-specific. Urine usually measures a major melatonin metabolite and can integrate secretion over a collection period, while its temporal resolution depends on collection intervals, completeness, and handling of creatinine or volume. Values, thresholds, and uses cannot be transferred directly between these specimens.
Dim-light melatonin onset
Dim-light melatonin onset, or DLMO, is a commonly used marker of internal circadian phase. It estimates when melatonin begins a sustained rise under dim conditions. It is derived from a series of specimens spanning the expected rise rather than one evening or morning sample. The collection window usually depends on sleep diaries or actigraphy from preceding days. Starting too late can miss onset, and ending too early can make calculation impossible.
DLMO may be calculated with a fixed concentration threshold or a rule relative to the individual's baseline, and methods can yield different times. Reports should state sampling interval, lighting conditions, timing deviations, analytical detection limit, threshold and interpolation method, and whether an unclear curve prevented calculation. A result that cannot be calculated may reflect the window, light exposure, adherence, or analytical sensitivity; it does not by itself mean the body produces no melatonin.
Home collection and preanalytical control
During home DLMO collection, the protocol should maintain dim conditions and document unexpected bright light, screen exposure, sample times, and actual sleep time. Bright or short-wavelength-enriched light can suppress or delay the observed melatonin rise. Every tube needs an accurate time and sequence label. Missing, swapped, or substantially late samples can distort the curve. Storage temperature, freezing, and transport must follow conditions validated for the kit.
Food, drink, caffeine, alcohol, smoking, tooth brushing, oral bleeding, food dyes, and some medicines can affect the specimen or assay. Users should follow the stated restrictions and rinse interval and document deviations. A melatonin supplement introduces exogenous hormone into blood, saliva, and urine and can prevent assessment of endogenous timing. Whether it should be withheld, and for how long, must be decided by the ordering professional for the intended purpose and formulation; necessary treatment should not be stopped independently.
Analytical methods and quality assurance
Radioimmunoassay, enzyme immunoassay, and liquid chromatography-tandem mass spectrometry differ in sensitivity, specificity, sample volume, and bias at low concentrations. Immunoassays can show cross-reactivity and lot effects, while mass spectrometry still requires controlled recovery, matrix effects, calibration, and carryover. Identical units do not make results or DLMO thresholds from different laboratories automatically equivalent.
Laboratories should validate detection and quantification limits, precision, accuracy, linear or reportable range, specimen stability, and interference, and use low-level controls, replicates, and appropriate calibration. DLMO depends particularly on reliable measurement near the low baseline before the rise. If a method cannot separate baseline from early increase, the estimated time can shift. Values below quantification should not simply be recorded as zero, and the concentration sequence and quality flags should remain available for review.
Clinical interpretation and diagnostic limits
Assessment of a circadian rhythm sleep-wake disorder begins with sleep history, work and school demands, sleep logs, and actigraphy. DLMO may add information when a case is complex or precise phase is important. Phase time must be interpreted in relation to the desired sleep episode: the same DLMO can create different phase relationships for different sleep targets. One melatonin concentration does not measure sleep quality and cannot diagnose insomnia or obstructive sleep apnea.
Age, puberty, pregnancy, ocular light perception, medication, shift work, and recent light history can affect timing or concentration. A population interval cannot be mechanically converted into one person's best bedtime. If schedule, season, light environment, specimen method, or algorithm differs between tests, an apparent change may not be a treatment effect. A normal result does not exclude symptoms, and an unusual result should first prompt review of adherence and clinical context.
Safe use and next actions
Before selecting a kit, users should determine whether it measures human melatonin or supplement content, which specimen it accepts, whether it is research-only, who analyzes it, how home lighting and timing are controlled, and who interprets an abnormal or indeterminate curve. A product with only one or two uncontrolled time points generally lacks support for precise diagnosis of a circadian disorder, calculation of an individualized treatment time, or evaluation of every sleep complaint.
A report should not prompt an unsupervised increase in melatonin dose, alteration of prescription treatment, all-night light exposure, or forced schedule shifting. Melatonin and light interventions are phase dependent; incorrect timing may be ineffective or move the rhythm in the opposite direction. Persistent insomnia, marked daytime sleepiness, snoring with breathing pauses, or inability to adapt to required schedules calls for symptom-directed sleep-medicine assessment. A kit is a measurement tool for a defined protocol, not a self-treatment instruction.